Highlight
- Proactive fecal calprotectin (FC) home monitoring every 2 months did not reduce risk or delay time to symptomatic ulcerative colitis (UC) flare compared to standard care.
- No differences were seen in secondary outcomes including healthcare utilization, medication use, or quality of life.
- Among patients who escalated therapy after confirmed high FC, flare frequency was numerically lower but without statistically significant risk reduction.
- The study suggests that home FC monitoring alone, without a strict escalation protocol, may not prevent UC flares, indicating a need for further research on optimal use and intervention strategies.
Background
Specialty calculators
For clinical reference; use professional judgment.
